Free Trial

Insmed (INSM) Stock Forecast & Price Target

$75.97
+0.91 (+1.21%)
(As of 07/19/2024 ET)

Insmed - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 16 Wall Street analysts who have issued ratings for Insmed in the last 12 months, the stock has a consensus rating of "Buy." Out of the 16 analysts, 16 have given a buy rating for INSM.

Consensus Price Target

$74.50
-1.93% Downside
High Forecast$102.00
Average Forecast$74.50
Low Forecast$42.00

According to the 16 analysts' twelve-month price targets for Insmed, the average price target is $74.50. The highest price target for INSM is $102.00, while the lowest price target for INSM is $42.00. The average price target represents a forecasted downside of -1.93% from the current price of $75.97.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
16 Buy rating(s)
11 Buy rating(s)
10 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$74.50$60.31$44.64$43.55
Forecasted Upside-1.93% Downside36.37% Upside67.63% Upside129.16% Upside
Get Insmed Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

INSM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

INSM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Insmed Stock vs. The Competition

TypeInsmedMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside-1.93% Downside1,424.45% Upside9.99% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/12/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$60.00 ➝ $85.00+11.07%
7/10/2024The Goldman Sachs Group
2 of 5 stars
 Boost TargetBuy ➝ Buy$74.00 ➝ $102.00+42.98%
7/9/2024Guggenheim
3 of 5 stars
 Boost TargetBuy ➝ Buy$70.00 ➝ $95.00+36.08%
7/8/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$70.00 ➝ $90.00+28.57%
7/5/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$83.00 ➝ $83.00+24.51%
7/1/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$68.00 ➝ $88.00+31.34%
6/21/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$42.00 ➝ $75.00+12.83%
6/20/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
6/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$55.00 ➝ $72.00+9.79%
6/7/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$36.00 ➝ $82.00+43.43%
5/31/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$39.00 ➝ $67.00+18.58%
5/29/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$45.00 ➝ $67.00+37.15%
5/29/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$55.00 ➝ $77.00+58.66%
5/29/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$46.00 ➝ $58.00+19.51%
5/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$40.00 ➝ $63.00+31.09%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$42.00+53.06%
2/24/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$46.00+128.40%
10/27/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$52.00 ➝ $50.00+197.27%
10/21/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$56.00 ➝ $53.00+185.71%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:51 AM ET.

INSM Forecast - Frequently Asked Questions

What is Insmed's forecast for 2024?

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Insmed is $74.50, with a high forecast of $102.00 and a low forecast of $42.00.

Should I buy or sell Insmed stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INSM shares.

Does Insmed's stock price have much upside?

According to analysts, Insmed's stock has a predicted upside of 28.07% based on their 12-month stock forecasts.

Do Wall Street analysts like Insmed more than its competitors?

Analysts like Insmed more than other "medical" companies. The consensus rating for Insmed is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how INSM compares to other companies.


This page (NASDAQ:INSM) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners